

Contents

1	Epidemiology	1
	<i>Andreas J. Gross and Christopher Netsch</i>	
1.1	Prevalence and Incidence of LUTS and BPS	2
1.2	Natural Course and Risks of Progression	3
1.3	BPS in Germany: Herne LUTS/BPS Study	4
	References	6
2	Anatomy of the Prostate	9
	<i>Andreas J. Gross</i>	
2.1	Introduction	10
2.2	Structure	10
	References	13
3	Pathophysiology	15
	<i>Stephan Madersbacher</i>	
3.1	Introduction	16
3.2	Histology	16
3.3	Endocrinology	16
3.4	Concept of Age-Associated Tissue Remodeling	19
3.5	Lifestyle Factors	19
3.6	Metabolic Syndrome	19
3.7	Bladder Dysfunction	20
	References	22
4	Symptomatology	23
	<i>Benedikt Becker</i>	
4.1	Complications and Late Effects	25
4.2	Classification of Benign Prostate Syndrome	26
4.3	Symptom Scores	26
	References	29
5	Clinical Diagnostics	31
	<i>Benedikt Becker</i>	
5.1	Medical History	32
5.2	Assessment of the Upper Urinary Tract	32
5.3	Physical Examination	33
5.4	Urinalysis	33
5.5	Prostate-Specific Antigen	33
5.6	Kidney Function Measurement	34
5.7	Optional Diagnostics	34
	References	34

6	Imaging Techniques for the Benign Prostate Syndrome	37
	<i>Matthias Oelke</i>	
6.1	Introduction	38
6.2	Ultrasound	38
6.3	Other Methods	46
	References	48
7	Endoscopy	51
	<i>Benedikt Becker</i>	
7.1	Indication	52
7.2	Cystoscopes	52
7.3	Procedure	52
7.4	Diagnostic Performance in BPH	53
7.5	Conclusions	56
	References	57
8	Uroflow and Residual Urine	59
	<i>Clemens Mathias Rosenbaum</i>	
8.1	Uroflowmetry	60
8.2	Residual Urine	62
	References	63
9	Urodynamics	65
	<i>Clemens Mathias Rosenbaum</i>	
9.1	Introduction	66
9.2	Procedure	67
9.3	Cystometry	68
9.4	Pressure-Flow Measurement	69
9.5	Other Examination Techniques	72
	References	73
10	Controlled Waiting	75
	<i>Andreas J. Gross</i>	
10.1	Principle	76
10.2	Indication	76
10.3	Risk Factors	76
10.4	Assessment	79
	References	79
11	Pharmacological Therapy	81
	<i>Lukas Lusuardi</i>	
11.1	Phytopharmaceuticals	82
11.2	Alpha-Blockers	83
11.3	5-Alpha-Reductase Inhibitors	87
11.4	Phosphodiesterase Inhibitors	88
11.5	Antimuscarinics	89
11.6	Beta-3-Agonist Mirabegron	89
11.7	Combination Therapies	89
	References	92

12	Surgical Techniques: Basics	99
	<i>Christopher Netsch</i>	
12.1	Surgical Basics	100
12.2	Surgical Principles: Vaporization, Enucleation, Resection	100
12.3	Lasers: Basic Knowledge	101
12.4	Lasers in the Treatment of Benign Prostatic Hyperplasia (BPH)	106
	References	111
13	Ablative Procedures: Enucleation	113
	<i>Christopher Netsch</i>	
13.1	Open Simple Prostatectomy (OSP)	114
13.2	Laparoscopic Simple Prostatectomy (LSP)	116
13.3	Robot-Assisted Simple Prostatectomy (RASP)	116
13.4	Transurethral Enucleation of the Prostate	118
13.5	Conclusions	125
	References	126
14	Ablative Procedures: Resection	131
	<i>Christopher Netsch</i>	
14.1	Introduction	132
14.2	Transurethral Resection of the Prostate (TUR-P)	132
14.3	Ablative Procedures: Thulium VapoResection of the Prostate (ThuVAP)	138
	References	140
15	Ablative Procedures—Vaporization: Bipolar and Photoselective Vaporization of the Prostate	143
	<i>Malte Rieken</i>	
15.1	Bipolar Transurethral Vaporization of the Prostate	144
15.2	Greenlight Laser Vaporization of the Prostate (PVP, Photoselective Vaporization of the Prostate)	145
	References	149
16	Ablative Procedures—Robotics	151
	<i>Malte Rieken</i>	
16.1	Procedure and Mechanism of Action	152
16.2	Functional Results	153
16.3	Peri- and Postoperative Safety	154
16.4	High Risk Patients	156
	References	156
17	Non-Ablative Procedures	159
	<i>Malte Rieken</i>	
17.1	Urolift®	160
17.2	Rezum®	162
17.3	iTind®	164
17.4	Prostatic Arterial Embolization (PAE)	166
	References	167

18	Economic Aspects of BPS	171
	<i>Andreas J. Gross</i>	
18.1	Life Expectancy	172
18.2	Cost Relevance of a Therapy	173
18.3	Costs of Lost Working Time	173
18.4	Costs due to Complications After Surgery	174
18.5	Overall View	174
	References	174
19	Patient Selection	177
	<i>Andreas J. Gross</i>	
19.1	Differential Diagnosis	178
19.2	Factors Influencing the Indication	181
19.3	Morbidity and Follow-Up Treatment Rate	187
19.4	Individual Therapy between Expectations and Reality	188
	References	189
20	Guidelines	191
	<i>Christopher Netsch</i>	
20.1	What is the Purpose of a Guideline?	192
20.2	Effectiveness and Quality of Guidelines	193
20.3	Criticism and Error-Proneness of Guidelines	194
20.4	Comparison of EAU, AUA and DGU Guidelines	195
20.5	Summary	205
	References	206
21	Prevention of Benign Prostate Syndrome	207
	<i>Matthias Oelke</i>	
21.1	Forms of Prevention	208
21.2	Primary Prevention	208
21.3	Secondary Prevention	211
21.4	Conclusions	214
	References	217
22	The Geriatric Patient	219
	<i>Peter Olbert</i>	
22.1	Introduction and Definitions	220
22.2	The Importance of Pre-Therapeutic Evaluation: The Geriatric Assessment	221
22.3	Specifics of the Pharmacological Therapy of BPS in the Geriatric Patient	222
22.4	Surgical Therapy in Geriatric Patients—Outcomes and Complications	226
	References	227
23	Controversies in Conservative and Surgical BPS Therapy	231
	<i>Christopher Netsch and Andreas J. Gross</i>	
23.1	Does the Normal-Sized Prostate Correspond to A Chestnut, is it 20 g in Size?	234
23.2	Is there a Bladder Outlet Obstruction (BOO) in Case of a Large Prostate?	234

23.3	Are Bladder Trabeculae Composed of Hypertrophied Muscle and are they Signs of Bladder Outlet Obstruction (BOO)?	234
23.4	What are Bladder Diverticula and Bladder Pseudodiverticula?	235
23.5	Is Urethrocystoscopy Suitable for the Diagnosis of Bladder Outlet Obstruction (BOO)?	235
23.6	Does BPS Progress in Stages?	236
23.7	Is Residual Urine Formation Caused by Bladder Outlet Obstruction?	236
23.8	Does Residual Urine (RU) Lead to Urinary Tract Infections (UTIs)?	237
23.9	Does RU Lead to Urinary Retention?	237
23.10	Does RU Formation Lead to Renal Dysfunction?	238
23.11	Can Drugs Reduce Bladder Outlet Obstruction (BOO)?	238
23.12	“Transurethral Enucleation Procedures take too Long Time. For Open Simple Prostatectomy (OSP) I just need 40 min”	239
23.13	Is Resection to the Prostate Capsule Essential for an Optimal Result of TUR-P?	239
23.14	What is Meant by Long-Term Data in Surgical BPS Therapy?	240
23.15	Is a Histology Necessary After the Surgical Treatment of BPS?	240
23.16	Can I Perform a HoLEP with the Thulium Laser?	241
23.17	Are the Clinical (Long-Term) Data for GreenLight Vaporisation of the Prostate (PVP), Aquabeam®, iTind®, Rezum® and Urolift® convincing?	241
23.18	Is it Possible to Treat a 150-g Prostate by TUR-P?	242
23.19	Is the Learning Curve (LC) of (Laser) Enucleation of the Prostate Longer than that of TUR-P?	243
23.20	We Perform Robotic-Assisted Simple Prostatectomy (RASP) Because Patients are Incontinent and Bleed After Transurethral Enucleation.	244
23.21	“The GreenLight Laser Is Not Suitable for BPS Surgery. Finally, You Have To Take the Loop.” Is a Surgical (Laser) Procedure for the Treatment of BPS Unreasonable, Because Finally One Takes a Loop for Coagulation?	244
23.22	We Perform Transurethral (Laser) Enucleation of the Prostate in Prostates larger than 60 g, Below that TUR-P Because of Training the Residents. We Perform Open Simple Prostatectomy Because of Training the Residents.	245
23.23	Are more Patients Incontinent After Laser Surgery of the Prostate than After TUR-P?	245
23.24	Do Patients Develop more Urge Symptoms After Laser Surgery of the Prostate than After TUR-P and Open Simple Prostatectomy (OSP)?	246
23.25	Do have New-Minimally Invasive Procedures such as Aquabeam®, Rezum® or Urolift® No Serious Complications?	247
	References	249